📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression. (2023)

First Author: González-Martínez I

Attributed to: Preclinical Development of Peptide Oligonucleotides for Myotonic Dystrophy Type 1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.omtn.2023.09.001

PubMed Identifier: 37744174

Publication URI: http://europepmc.org/abstract/MED/37744174

Type: Journal Article/Review

Volume: 34

Parent Publication: Molecular therapy. Nucleic acids

ISSN: 2162-2531